glp-1 agonists and retained gastric contents at endoscopy GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS BUT NOT INCREASED RISK OF MAJOR ADVERSE ANESTHESIA-RELATED EVENTS DURING UPPER glp-1 drug comparison medications Quantity:6 Months Optimizes Fat Metabolism

glp-1 agonists and retained gastric contents at endoscopy GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS BUT NOT INCREASED RISK OF MAJOR ADVERSE ANESTHESIA-RELATED EVENTS DURING UPPER glp-1 drug comparison medications Quantity:6 Months Optimizes Fat Metabolism

glp-1 drug comparison medications compared: Benefits and differences Currently available GLP-1 RAs. | –

Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study

Optimizes Fat Metabolism

Quantity:6 Months

DOI: Published online: February 14, 2024 1 Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK 2 Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland Corresponding author: Adie Viljoen